THE PEER-REVIEWED FORUM FOR EVIDENCE IN BENEFIT DESIGN ™ MARCH/APRIL 2012
VOLUME 5, NUMBER 2
FOR PAYERS, PURCHASERS, POLICYMAKERS, AND OTHER HEALTHCARE STAKEHOLDERS
EDITORIAL
A New Beginning David B. Nash, MD, MBA BUSINESS
Trends in Biologic Therapies for Rheumatoid Arthritis: Results from a Survey of Payers and Providers ™
Rhonda Greenapple, MSPH Stakeholder Perspective by Albert Tzeel, MD, MHSA, FACPE
Impact of the Removal of the Monthly Liver Function Test Requirement for Ambrisentan Louise A. Durst, RN; John Carlsen, MHA; Megan Kuchinski, MPH; Lauren Harner, JD; Daniel Neves, BA; Stephanie J. Harris, RN, BSN; Glenna L. Traiger, RN, MSN, CNS-BC Stakeholder Perspective by James T. Kenney, Jr, RPh, MBA CLINICAL
Benefits of Novel Oral Anticoagulant Agents for Thromboprophylaxis after Total Hip or Knee Arthroplasty Richard J. Friedman, MD, FRCSC Stakeholder Perspective by Atheer A. Kaddis, PharmD
©2012 Engage Healthcare Communications, LLC www.AHDBonline.com